Business Context and Reporting Period
This Form 8-K Current Report was filed by Becton, Dickinson and Company (BD) on October 22, 2020. The filing reports on corporate governance changes regarding the appointment of certain officers, effective January 1, 2021.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The material change reported is the restructuring of senior leadership roles within the Life Sciences Segment and the Technology function:
- Patrick K. Kaltenbach: Appointed as Executive Vice President and Chief Technology Officer, effective January 1, 2021. He currently serves as Executive Vice President and President of the Life Sciences Segment.
- David Hickey: Appointed as President of the Life Sciences Segment, succeeding Mr. Kaltenbach, effective January 1, 2021. He currently serves as President of BD's Integrated Diagnostics Solutions business unit.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on market conditions, risks, contingencies, or unusual items.
Investor Verification Checklist
- Confirm the effective date of the leadership transition (January 1, 2021).
- Verify the current titles and responsibilities of Patrick K. Kaltenbach and David Hickey prior to the transition.
- Review subsequent filings for any impact these leadership changes may have on the Life Sciences Segment strategy or technology roadmap.